Daiichi Sankyo's edoxaban enters pivotal trial for VTE
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo has begun recruiting for a key Phase III multinational clinical trial programme for its oral direct Factor Xa inhibitor, edoxaban.